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obtained from 1225 patients [709 male, 516 female]. The average age of the 
patients was found to be 56.8±0.5 years. The average number of medications 
prescribed was 10.6±0.2. 585 patients were found to be aged 60 years or more and 
613 patients were in the age group 18-60 years. Out of the 1225 patients, 848 did 
not have any medication error. An error was noted on only in 377 patient 
profiles. The total number of medication errors was found to be 638. Of these, 
597 were errors ‘with no harm’ and only 41 were errors ‘with harm’. Of these 
medication errors, drug interactions (DIs) were found to be leading the list with 
50% of the medication errors. Cardiovascular agents contributed maximum to 
the DIs followed by anticoagulants and antimicrobial agents. Only 172 DIs had a 
moderate severity. DIs was followed by duplication of therapy (20%), incorrect 
interval (10%), monitoring error, incompleteness of prescription, omission error 
and overdosing, respectively. CONCLUSIONS: These results confirm that drug 
interaction continue to lead the list of medication errors in Indian tertiary health 
care settings. The study is ongoing to determine the interventions to reduce the 
errors.  
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OBJECTIVES: Compared to adults relatively little is known about drug safety in 
children. This study aims to describe the drugs and adverse events most 
commonly reported in the US spontaneous Adverse Event Reporting System 
(AERS) in children. METHODS: Adverse events reported to the US FDA AERS 
Database between 1 January 2007 and 30 June 2012 and occurring in children and 
adolescent (<18 years old) were examined. Demographic characteristics of the 
patients and reports were described by age, gender and reporter type. 
Additionally, the most commonly suspected drugs and the most frequently 
occurring adverse events in the AERS database were identified. RESULTS: We 
identified a total of 90,355 reports (average 16,428 reports/year) of primary 
suspect medications in children, of which 60.8% were for individuals < 12 years 
old and 50.6% were males. Physicians (30.5%) and consumers (27.4%) reported 
the majority of pediatric adverse drug events. Methylphenidate was the most 
frequently reported drug with 3,755 (4.2%) reports, followed by infliximab (3.0%) 
and isotretinoin (2.7%). Vomiting (1.3%), pyrexia (1.2%), convulsion (1.1%), drug 
ineffective (1.0%) and product quality issue (0.9%) were the top five reported 
adverse events. However, dyspnoea and pneumonia became the fourth and fifth 
leading adverse events respectively when restricting our analysis to only severe 
events (i.e., resulting in hospitalization, life-threatening events, or death). 
CONCLUSIONS: Data from post-marketing surveillance of adverse events can 
add to our understanding of drug safety in children. A large proportion of events 
reported to the FDA are not considered severe and focusing solely on severe 
events is likely important to identify potential high risk medications. Subsequent 
analyses of the most commonly reported drug causes of severe adverse events 
may lead to important safety questions.  
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OBJECTIVES: Pharmacological treatment is effective in reducing hazardous 
drinking in persons with alcohol dependence, while little is known whether it is 
effective in HIV patients. The purpose of this study was to examine feasibility 
and effectiveness of using pharmacotherapy (naltrexone) on women infected 
with HIV. METHODS: The NIAAA-sponsored pilot study was a double-blind, 
randomized controlled trial. Women with HIV who met criteria for NIAAA-
defined past-year hazardous drinking were recruited from HIV clinical settings in 
Jacksonville (FL) and the Women’s Interagency HIV Study (WIHS) in Chicago (IL) 
and Washington DC. Participants were randomized 2:1 to oral naltrexone (50mg) 
or placebo for 4 months; outcomes were assessed 2, 4 and 7 months after 
enrollment. RESULTS: From December, 2010 to February, 2012, 19 women were 
enrolled (mean age 48.8 years, 95% African American). Approximately 70% of 
eligible women were successfully enrolled at two WIHS sites, compared with 12% 
at the clinical site in Jacksonville (FL). Almost all women reported prior use of 
other drugs (heroin, 3; methadone, 3; cocaine, 13; marijuana, 14; tobacco, 16). 
Among 14 (74%) women who completed the study, average daily alcohol 
consumption dropped significantly from 7.13 standard drinking units (SDUs) at 
baseline to 0.46 SDUs at month 7. CONCLUSIONS: Although the sample is small, 
this pilot study demonstrates the feasibility of conducting a larger study to 
determine the impact of naltrexone on alcohol consumption and health 
outcomes in women with HIV. Although enrollment of HIV-infected women into 
alcohol treatment trials can be challenging, we demonstrated that these 
challenges can be minimized by recruiting from previously established long term 
cohorts that directly address alcohol consumption. Health outcome, especially 
alcohol consumption reduction, reported in this study will provide valuable 
input for future decision analytical models to evaluate the cost-effectiveness of 
using pharmacotherapy treating hazardous drinking among HIV patients.  
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OBJECTIVES: There is no safe range for Blood Lead Levels (BLL) in humans. Lead 
is associated with many adverse health outcomes in children because of more 
susceptibility to environmental lead. We aimed to explore a convenient and cost-
effective strategy for decreasing BLL among adolescent with the objective to 
assess the effect of Ascorbic-acid on BLL among school going adolescent of 
Karachi. METHODS: A cluster randomized trial was conducted in schools, 
randomized to 250mg or 500mg of Ascorbic-acid (four clusters each). BLL was 
measured at baseline and after four weeks of intervention. Lead exposure was 
assessed through a questionnaire at baseline and dietary Vitamin-C through 
Food Frequency Questionnaire (FFQ) at follow-up. The cluster adjusted difference 
between the groups calculated through independent t-test and within group 
difference through paired t-test. A multiple-linear-regression model was built for 
adjusting residual confounders. RESULTS: A total 144 individuals were recruited. 
The overall mean BLL at baseline was 12.9mg/dl (95%CI; 12.2-13.8). For Ascorbic-
acid 250mg and 500mg it was 13.4mg/dl (95%CI; 12.1-14.7) and 12.5mg/dl (95%CI; 
11.7-13.4) respectively. The mean decline in BLL was 2.7mg/dl (p=0.002) and 
3.29mg/dl (p<0.001) in 250mg and 500mg respectively. The mean difference in 
BLL decline between two group was 0.6mg/dl (p=0.824). On an average, for one 
mg/dl increase in baseline BLL, the decreased was 0.8mg/dl after adjusting for 
chipping-off of school paint and intervention group (p<0.001). CONCLUSIONS: 
The overall mean baseline BLL of our sampled population was above  
the acceptable level recommended by CDC (10mg/dl). Oral supplementation  
of Ascorbic-acid in both 250mg & 500mg significantly decreased BLL. However, 
the dose dependent decline was statistically insignificant. In adolescent who  
had initially elevated BLL showed greater decline at follow-up. Thus, using 
Ascorbic-acid 250mg or 500mg daily could be a cheap, safe and easily available 
strategy to lower BLL among adolescent particularly those living in highly 
exposed areas.  
 
PIH6  
DRUG USE EVALUATION AT AN INDIAN PUBLIC TEACHING HOSPITAL  
Tiwari P1, Kumar A2, Sachdev A3, D'cruz S3 
1National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. NAGAR, India, 
2NIPER, SAS NAGAR, India, 3Govt Med Coll Hosp, Chandigarh, India  
OBJECTIVES: To evaluate prescribing pattern in an inpatient setting of a public 
teaching hospital in India. METHODS: Patient records were collected from 
general medicine wards of a public teaching hospital over a period of 7 months. 
The data were analyzed using WHO recommended prescribing indicators: The 
National List of Essential Medicines-2003 of India (NLEM-2003) was used to 
analyze prescribing from essential drug list. The results were presented as 
average±SEM, median (inter quartile range) and percentages, as applicable. 
RESULTS: A total of 710 inpatients’ records were analyzed. Over two thirds of 
patients (67.6%) had only one diagnosis and the average number of diagnosis 
was 1.4±0.02. The average number of medicines prescribed was found to be 7.3. 
The percentage of medications prescribed from NLEM was 65%. Approximately 
14.6% medications were prescribed by generic names. The percentage of 
prescriptions with an injection(s) and antibiotic(s) were 85.9% and 68.6%, 
respectively. CONCLUSIONS: This study has provided real-time evidence that the 
prescribers in public teaching hospital were aware of the NLEM-2003. There are 
areas, in addition to this, which require consolidation to promote rational drug 
therapy.  
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OBJECTIVES: To conduct a systematic literature review to assess the prevalence, 
incidence, and treatment rates of hypogonadism in men across geographies. 
METHODS: The literature search was undertaken within the PubMed/MEDLINE, 
Embase, and Cochrane databases for articles published between 1992 and 2012. 
Articles were excluded from this review if the sample size was less than 30. 
RESULTS: We reviewed 175 citations/abstracts and identified 109 relevant 
articles. Numerous cut-off points for testosterone level were used to define 
hypogonadism; however, the most widely used definitions were total 
testosterone <300 ng/dL (10.41nmol/L) and free testosterone <5ng/dL 
(<0.174nmol/L). Few studies used the combination of symptoms and testosterone 
level cut-off points to define hypogonadism. The prevalence, incidence, and 
treatment rates of hypogonadism across studies varied widely depending upon 
the population studied and how hypogonadism was defined. The overall 
prevalence rates for hypogonadism based on population-based studies were: US, 
3.8% - 20.4%; Chile, 28.1%; Germany, 3.4% - 5%; Finland, 19.8%; Malaysia, 6.0% - 
16.1%; Taiwan, 12.0% and Hong Kong, 9.5%. Prevalence also increased with age 
and in the presence of co-morbid conditions. The incidence per 1000 person-
years was 12.3 in the US and 11.7 in Germany. Treatment rates varied 
dramatically in different studies and populations and were generally very low 
(9.6% - 11.3% of men with hypogonadism). CONCLUSIONS: The literature review 
suggested that there is potentially a significant burden of hypogonadism in the 
general population. Burden seems to increase with age and in the presence of 
certain disease conditions. Inconsistent disease definitions and diagnostic 
